Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

178
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
11/19/2014 11/20/2014 11/21/2014 11/24/2014 11/25/2014 Date
91.5(c) 91.5(c) 91.95(c) 91.55(c) 91.2(c) Last
5 524 823 3 605 158 5 430 800 4 577 005 6 864 921 Volume
-0.27% 0.00% +0.49% -0.44% -0.38% Change
More quotes
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers... 
Sector
Pharmaceuticals
Calendar
01/27Earnings Release
Surperformance© rating of Novartis AG
Trading Rating : Investor Rating :
More about the company
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 58 474 M
EBIT 2014 14 900 M
Net income 2014 10 667 M
Debt 2014 5 293 M
Yield 2014 2,82%
Sales 2015 57 198 M
EBIT 2015 15 666 M
Net income 2015 11 354 M
Debt 2015 7 034 M
Yield 2015 2,99%
PER 2014 22,19
PER 2015 20,47
EV / Sales 2014 4,46x
EV / Sales 2015 4,59x
Capitalization 255 625 M
More Financials
Latest news on NOVARTIS AG
1d ago NOVARTIS : European Commission approves Novartis' Signifor to treat patients wit..
1d ago NOVARTIS : Tata Memorial to repay cancer patients
1d ago NOVARTIS : MILITARY $19,207 Federal Contract Awarded to Alcon Laboratories
1d ago NOVARTIS : Alcon Research Assigned Patent
1d ago GLAXOSMITHKLINE : calls investors to vote for trade with Novartis
1d ago NOVARTIS : announces extension to FDA review period for multiple myeloma investi..
1d ago NOVARTIS : announces extension to FDA review period for multiple myeloma investi..
2d ago GLAXOSMITHKLINE : GSK shareholders to vote on Novartis deal on Dec. 18
2d ago VECTURA : Interim Results for the six months ended 30 September 2014
2d ago NOVARTIS : Foundation symposium showcases sustainable healthcare interventions
2d ago NOVARTIS : Foundation symposium showcases sustainable healthcare interventions
2d ago NOVARTIS : Cosentyx receives positive CHMP opinion for first-line treatment of m..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF